# Lakefront Biotherapeutics NV (LKFT)

Source page: https://stoqly.net/companies/lkft

- **Ticker:** LKFT (Nasdaq)
- **Sector:** Health Care / Pharmaceutical Preparations
- **SEC CIK:** 0001421876
- **Latest annual report:** 20-F filed 2026-03-26 (https://www.sec.gov/Archives/edgar/data/1421876/000110465926035163/glpg-20251231x20f.htm)
- **Data updated:** 2026-11-01

## Key figures

- **Last close:** $32.28 on 2026-10-30
- **Market cap:** $2.1B
- **P/E (trailing):** 5.9x
- **EPS, trailing 12 months:** $5.49
- **Revenue (FY2025):** $1.3B
- **Revenue growth:** +320.6%
- **Revenue growth, 5-year CAGR:** +18.1%
- **Gross margin:** 97.3%
- **Operating margin:** 26.5%
- **Net margin:** 28.9%
- **Free cash flow:** −$306M
- **Free cash flow margin:** −24.4%
- **Return on equity:** 10.6%
- **Change in share count:** 0.0%
- **Piotroski F-score:** 6/9
- **Insider buys, last 90 days:** $0.0M
- **Insider sells, last 90 days:** $0.0M

Definitions: https://stoqly.net/about

## Annual results

From SEC EDGAR XBRL filings. Full table: https://stoqly.net/companies/lkft/figures.csv

| US$ millions | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| Revenue | 143 | 143 | 329 | 935 | 545 | 277 | 254 | 259 | 298 | 1,254 |
| Operating income | -13 | -101 | -56 | 413 | -204 | -203 | -138 | -95 | -204 | 333 |
| Net income | 60 | -130 | -35 | 168 | -348 | -122 | -229 | 229 | 80 | 362 |
| Diluted EPS (US$) | 1.26 | -2.64 | -0.66 | 2.79 | -5.35 | -1.87 | -3.49 | 3.47 | 1.21 | 5.49 |
| Operating cash flow | 265 | -166 | -168 | 3,592 | -487 | -596 | -526 | -439 | -346 | -290 |
| Free cash flow | 260 | -172 | -180 | 3,567 | -536 | -660 | -555 | -459 | -364 | -306 |
| Cash | 1,026 | 1,381 | 1,478 | 2,091 | 2,620 | 2,530 | 542 | 184 | 67 | 103 |

---

Source: SEC EDGAR filings and end-of-day prices, via Stoqly. For information only — not investment advice or a recommendation to buy, sell or hold any security.